OUTCOMES FOR PATIENTS WITH NON-METASTATIC TRIPLE-NEGATIVE BREAST

1J. Ben Hassoun, 1Y. Charfi, 1R. Chargui, 1K. Rahal, 1S. Zouari, 1D. El Asri, 1S. Zarka, 1S. Tamez, 1R. Belhaj, 1M. Amine, 1A. Hamdi, 1M. Tounsi, 1S. Azaiez.
1Centre Hospitalier Universitaire Tunis Centre de Cancérologie, Tunis, Tunisia.
1Centre Hospitalier Universitaire Tunis Centre de Radiologie, Tunis, Tunisia.
1Salah Azaiez Institute, Surgical Oncology, Tunis, Tunisia.
1Salah Azaiez Institute, Anatomopathology, Tunis, Tunisia.
1Salah Azaiez Institute, Anesthesiology, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging, Tunis, Tunisia.
1Salah Azaiez Institute, Nuclear Medicine, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Physics, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Oncology, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Genetics, Tunis, Tunisia.
1Salah Azaiez Institute, Environmental Medicine, Tunis, Tunisia.
1Salah Azaiez Institute, Preventive Medicine, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Administration, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Economics, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Ethics, Tunis, Tunisia.
1Salah Azaiez Institute, Medical IT, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Library, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Quality, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Statistics, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Support, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Training, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Translation, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Writing, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Administration, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Administration, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Administration, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Administration, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Research, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Education, Tunis, Tunisia.
1Salah Azaiez Institute, Medical Imaging Administration, Tunis, Tunisia.
invasive breast cancer. The sequences of 85 patients who underwent a radical treatment (mastectomy) were compared to those of 84 patients who benefited from conservative surgery. We estimated the tumor volume (TV) and breast volume (BV) on enhanced MRI and then we compared the tumor volume to breast volume ratio (TV/BV) in both groups.

Results We reviewed retrospectively the preoperative MRI (3 Tesla) of 169 patients operated at Hôtel-Dieu de France for invasive breast cancer. The sequences of 85 patients who underwent a radical treatment (mastectomy) were compared to those of 84 patients who benefited from conservative surgery. We estimated the tumor volume (TV) and breast volume (BV) on enhanced MRI and then we compared the tumor volume to breast volume ratio (TV/BV) in both groups.

Conclusions Our data suggest that preoperative MRI can aid the surgical treatment decision in patients with invasive breast cancer by assessing the tumor to breast volume ratio as well as by providing a full mapping of multifocal and multicentric lesions in the breast tissue.

IGCS19-0697

THE ALTERATION OF LIPIDS AND STEROID HORMONES IN BREAST TUMORS

N Kotrikadze, N Nakashidze, R Ramishvili, M Alibegashvili, N Petrovic, P Peshkova, B Sepiashvili, M Gorgileini, S Gupta, M Variete, A Kalandia, S Ahmad. Ivane Javakhishvili Tbilisi State University, Department of Biology, Tbilisi, Georgia; Batumi Shota Rustaveli State University, Department of Biology, Batumi, Georgia; VInca Institute of Nuclear Sciences University of Belgrade, Department for Radiobiology and Molecular Genetics, Belgrade, Serbia; Batumi Shota Rustaveli State University, Department of Clinical Medicine, Batumi, Georgia; Batumi Shota Rustaveli State University, Department of Biochemistry, Batumi, Georgia; Florida Hospital Cancer Institute- Orlando- FL, Department of Gynecologic Oncology, Orlando- FL, USA

Objectives Breast Cancer (BC) is the mostly spread malignant disease among women worldwide. Lipids play important roles in several biochemical pathways on molecular and cellular level, such as synthesis of steroid hormones, which contributes to the development of BC. Therefore, we investigated levels following plasma lipids: cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and triglycerides (TG), and sex-steroid hormones: progesterone (P), estradiol (E2), testosterone (T).

Methods For the assessment of hormonal status, we used the blood samples of women with benign (fibroadenoma) and malignant tumors of breast gland within patients aged between 20 and 45 years. Also, control group of women were age-matched. Enzyme-linked immunoabsorbent assay (ELISA) was used for the quantitative determination of hormones, with appropriate ELISA kits.

Results The investigations have shown the levels of CA153, CA125, and CEA tumor markers, and sex-steroid hormones estrogen (E2), progesterone (P), and testosterone (T).

Conclusions According to our investigation, higher CHOL level were associated with benign (P=0.0001) and malignant (P=0.0002) tumors compared with control group. The level of HDL decreases in benign (P=0.0002) and malignant (P<0.001) tumor groups compared with the control group. LDL level was elevated in both groups, as well, in benign and malignant tumors respectively (P=0.002, P<0.001). VLDL level was also decreased in both tumor subtypes respectively (P=0.0001; P=0.0007) compared to control group. Similarly, TG level was increased in benign (P=0.0025), and in malignant breast tumors (P=0.002) compared with controls. E2 and T levels were elevated in tumors in tumor’s group (P<0.05).

Conclusions Our investigation has shown the association between high levels of CHOL, LDL, TG, E2 and T with breast tumors. Lipid profile and steroid hormones may be used as relatively reliable prognostic marker for early breast cancer prevention and diagnostics.

IGCS19-0722

SELECTED TUMOR MARKERS AND SEX-STEROID HORMONES IN BREAST TUMORS

N Nakashidze*, N Kotrikadze, E Gogitidze, R Ramishvili, N Petrovic, M Alibegashvili, N Kedelidze, N Lomtatidze, M Koridze, B Sepiashvili, D Baratakhshvili, S Ahmad, Ivane Javakhishvili Tbilisi State University, Scientific-Research Institute of Cellular and Molecular Medicine, Tbilisi, Georgia; Ivane Javakhishvili Tbilisi State University, Department of Biology, Tbilisi, Georgia; Batumi Shota Rustaveli State University, Department of Biology, Batumi, Georgia; VInca Institute of Nuclear Sciences University of Belgrade, Department for Radiobiology and Molecular Genetics, Belgrade, Serbia; Florida Hospital Cancer Institute, Department of Gynecologic Oncology, Orlando- FL, USA

Objectives Breast cancer (BC) is one of the tumors with the highest incidence among women worldwide. We have been investigating potential association between CA153, CA125, and CEA tumor makers, and sex-steroid hormones estrogen (E2), progesterone (P), and testosterone (T).

Methods For the assessment of hormonal status, we used the blood samples of women with benign (fibroadenoma) and malignant tumors of breast gland within patients aged between 20 and 45 years. Also, control group of women were age-matched. Enzyme-linked immunoabsorbent assay (ELISA) was used for the quantitative determination of hormones, with appropriate ELISA kits.

Results The investigations have shown the levels of CA153, CA125 and CEA tumors markers were high within patients with benign and malignant breast tumors. According to our studies levels of steroid hormones E2 and T were elevated in BC tumors (benign - P<0.001 and P=0.003; malignant - P=0.0003 and P=0.0424, respectively).

Conclusions In conclusion, the present study suggests that higher levels of CA 15–3, CA 125, CEA tumor markers and sex steroid hormones (E2, T) may be useful as a reliable prognostic marker for early breast cancer prevention and diagnostics. The association between mentioned tumor markers and sex-steroid hormones provides a new perspective a identify new combinative markers for breast cancer.

IGCS19-0470

METASTASIS DESCRIPTION IN 227 PATIENTS WITH BREAST CANCER IN COLOMBIA

GA Herrera Rueda, JS Insauty Enriquez, JF Lozano Jiménez, J Rueda Lara, D Reyes Cadenas*, Universidad Industrial de Santander UIS, Internal Medicine, Bucaramanga, Colombia

Objectives Background: Describing individuals with advanced breast cancer allows identifying some factors that influence the course of care. The objective of this study is to describe...